D-1459-2019 Class II Terminated
FDA drug recall D-1459-2019 was initiated by Macleods Pharma Usa Inc on Jun 20, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 142626 bottles (12,836,340 tablets).
Recall details
- Product Type
- Drugs
- Report Date
- Jul 17, 2019
- Initiation Date
- Jun 20, 2019
- Termination Date
- Oct 26, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 142626 bottles (12,836,340 tablets)
Product description
Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-050-10
Reason for recall
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Distribution pattern
Nationwide
Code information
BLK719A Sep-19 BLK720A Sep-19 BLK721A Sep-19 BLK722A Sep-19 BLK723A Sep-19 BLK724A Sep-19 BLK725A Oct-19 BLK726A Oct-19 BLK804A Jan-20 BLK806A Jan-20 BLK825A Oct-21 BLK826A Oct-21
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1459-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026